International Journal of Hematology and Oncology 2019, Vol 29, Num 2 Page(s): 108-116
Prognostic Value of IDH-1, PTEN and EGFR Expression in High Grade Gliomas

Meryem AKTAN1, Sidika FINDIK2, Gul KANYILMAZ1, Berrin Benli YAVUZ1, Mehmet KOC1

1Necmettin Erbakan University, Faculty of Medicine, Department of Radiation Oncology, Konya, TURKEY
2Necmettin Erbakan University, Faculty of Medicine, Department of Pathology, Konya, TURKEY

Keywords: Glioma, IDH, EGFR, PTEN
Gliomas are the most common primary brain tumors in adults. Despite advances in modern diagnostic procedures and therapies, the prognosis is still poor. To improve survival and the knowledge about the biological and clinical presentation of gliomas, more individualised and targeted treatments are needed. The aim of this study was to correlate the immunostaining patterns of isocitrate dehydrogenase-1 (IDH-1), phosphatase and tensin homolog (PTEN) and epidermal growth factor (EGFR) with progression-free survival (PFS) and overall survival (OS) in high grade gliomas patients. We analized 60 high grade gliomas who underwent surgery and standard chemoradiotherapy. Immunohistochemical methods were used to classify the IDH-1 gene mutation presence, staining patterns of PTEN and EGFR in tumor samples of the diagnosis. Median follow-up time was 18.9 months. There was significant relation between IDH-1 mutation and OS. Median OS was 37.9 months for patients with IDH-1 mutation, 12.4 months for patients with no mutation (p< 0.001). Median PFS was 29.8 months for patients with no IDH-1 mutation and 70.4 months for patients with IDH-1 mutation (p= 0.03). There was no significant relation between PTEN and EGFR immunopattern and OS or PFS in univariate analysis. However, there was significant relation between immunoreactivity of PTEN and OS (p= 0.03), immunointensity of PTEN and OS (p= 0.02) in multivariate analysis. In conclusion, the relationship between EGFR mutation and OS and PFS can also be demonstrated by studies with more patients.